Sign up to save your podcasts
Or
Share HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Featuring an interview with Dr Laura Huppert, including the following topics:
- General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00)
- Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44)
- Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30)
- Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13)
- Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25)
- CNS penetration and activity of ADCs in the treatment of breast cancer (22:27)
- Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24)
- Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05)
- Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51)
- Ongoing evaluation of ADCs in the localized disease setting (35:42)
- Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38)
CME information and select publications
View all episodes
By Dr Neil Love
4.6
112112 ratings
Featuring an interview with Dr Laura Huppert, including the following topics:
- General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00)
- Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44)
- Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30)
- Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13)
- Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25)
- CNS penetration and activity of ADCs in the treatment of breast cancer (22:27)
- Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24)
- Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05)
- Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51)
- Ongoing evaluation of ADCs in the localized disease setting (35:42)
- Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38)
CME information and select publications
More shows like Research To Practice | Oncology Videos
View all
JAMA Editors' Summary
138 Listeners
Gastrointestinal Cancer Update
17 Listeners
Lung Cancer Update
30 Listeners
Prostate Cancer Update
13 Listeners
Breast Cancer Update
71 Listeners
Gynecologic Oncology Update
13 Listeners
Hematologic Oncology Update
76 Listeners
Dermatologic Oncology Update
0 Listeners
NEJM This Week
322 Listeners
JAMA Clinical Reviews
499 Listeners
ASCO Daily News
57 Listeners
White Coat Investor Podcast
2,428 Listeners
The Curbsiders Internal Medicine Podcast
3,331 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
200 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
366 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing
0 Listeners